| pubmed-article:9829157 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9829157 | lifeskim:mentions | umls-concept:C0231441 | lld:lifeskim |
| pubmed-article:9829157 | lifeskim:mentions | umls-concept:C0076891 | lld:lifeskim |
| pubmed-article:9829157 | lifeskim:mentions | umls-concept:C0443218 | lld:lifeskim |
| pubmed-article:9829157 | lifeskim:mentions | umls-concept:C2827483 | lld:lifeskim |
| pubmed-article:9829157 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:9829157 | lifeskim:mentions | umls-concept:C1527129 | lld:lifeskim |
| pubmed-article:9829157 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9829157 | pubmed:dateCreated | 1999-1-25 | lld:pubmed |
| pubmed-article:9829157 | pubmed:abstractText | Verapamil sustained-release (SR)/trandolapril is a combination of a phenylalkylamine calcium antagonist and an angiotensin converting enzyme inhibitor for the management of essential hypertension. Verapamil SR/trandolapril does not adversely influence glucose, insulin or lipid parameters in patients with mild to moderate essential hypertension and type 2 (non-insulin-dependent) diabetes mellitus with or without elevated cholesterol and/or triglyceride levels. Verapamil SR/trandolapril reduces proteinuria to a greater extent than the individual components in patients with diabetic or non-diabetic proteinuria. The antihypertensive efficacy of once daily verapamil SR/trandolapril (180/1 or 180/2 mg) for 8 weeks or 6 months is similar to that of atenolol/chlorthalidone (100/25 mg) and lisinopril/hydrochlorothiazide (20/12.5 mg), and was at least as good as that of metoprolol/hydrochlorothiazide (100/12.5 mg) in a small trial. The reduction in sitting or supine diastolic and systolic blood pressure is greater after verapamil SR/trandolapril (180/2 to 240/4 mg) than after monotherapy with verapamil SR (180 and 240 mg/day) or trandolapril (2 to 8 mg/day). Fewer cardiac events occurred after verapamil SR/trandolapril (240/1 to 360/2 mg/day) than after trandolapril (1 to 2 mg/day) in postmyocardial infarction patients with congestive heart failure. The incidence of adverse events after verapamil SR/trandolapril is similar to that of comparator drugs and the individual components of the combination. | lld:pubmed |
| pubmed-article:9829157 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9829157 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829157 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9829157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829157 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829157 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9829157 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:9829157 | pubmed:issn | 0012-6667 | lld:pubmed |
| pubmed-article:9829157 | pubmed:author | pubmed-author:DooleyMM | lld:pubmed |
| pubmed-article:9829157 | pubmed:author | pubmed-author:GoaK LKL | lld:pubmed |
| pubmed-article:9829157 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9829157 | pubmed:volume | 56 | lld:pubmed |
| pubmed-article:9829157 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9829157 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9829157 | pubmed:pagination | 837-44; discussion 845-6 | lld:pubmed |
| pubmed-article:9829157 | pubmed:dateRevised | 2005-11-16 | lld:pubmed |
| pubmed-article:9829157 | pubmed:meshHeading | pubmed-meshheading:9829157-... | lld:pubmed |
| pubmed-article:9829157 | pubmed:meshHeading | pubmed-meshheading:9829157-... | lld:pubmed |
| pubmed-article:9829157 | pubmed:meshHeading | pubmed-meshheading:9829157-... | lld:pubmed |
| pubmed-article:9829157 | pubmed:meshHeading | pubmed-meshheading:9829157-... | lld:pubmed |
| pubmed-article:9829157 | pubmed:meshHeading | pubmed-meshheading:9829157-... | lld:pubmed |
| pubmed-article:9829157 | pubmed:meshHeading | pubmed-meshheading:9829157-... | lld:pubmed |
| pubmed-article:9829157 | pubmed:meshHeading | pubmed-meshheading:9829157-... | lld:pubmed |
| pubmed-article:9829157 | pubmed:meshHeading | pubmed-meshheading:9829157-... | lld:pubmed |
| pubmed-article:9829157 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9829157 | pubmed:articleTitle | Fixed combination verapamil SR/trandolapril. | lld:pubmed |
| pubmed-article:9829157 | pubmed:affiliation | Adis International Limited, Auckland, New Zealand. demail@adis.co.nz | lld:pubmed |
| pubmed-article:9829157 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9829157 | pubmed:publicationType | Review | lld:pubmed |
